Liver cancer is difficult to treat because tumors vary greatly from patient to patient. A team led by Markus Heim and Sandro Nuciforo at the University of Basel captured this diversity by building a collection of mini-tumors, which they used to systematically search for new treatment options. Their results, published in Cell Reports, describe new uses for approved drugs and new drug combinations, with one combination proving promising in an animal model.

Although immunotherapies have greatly improved treatment of liver cancer, they are not effective for all patients. Liver tumors can differ substantially in biology depending on factors such as the cause of the disease and genetic changes in the cancer cells, so they respond very differently to drugs.

For the study, researchers established a collection of 35 organoid lines from hepatocellular carcinoma, the most common form of liver cancer. These three-dimensional structures, made of living cancer cells, retain key characteristics of the original tumor. Such collections exist, but many of the Basel mini-tumors were grown from small samples obtained during diagnostic needle biopsies, so the collection includes advanced tumors underrepresented elsewhere. “Our collection reflects different stages of the disease, as well as liver tumors with various causes,” says Nuciforo, the study’s first author. “This allows us to test which drugs are effective despite the significant biological differences between the tumors.”

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

In an initial automated screening, the team tested 1,642 compounds—cancer drugs, experimental compounds, and drugs approved for other diseases—on four selected liver cancer organoids, then tested the most promising ones on a larger organoid set. Several drugs showed a potent anti-tumor effect. The team then searched specifically for drug combinations with different mechanisms of action. “Rather than focusing on a single vulnerability of the tumor, we combine drugs with different mechanisms of action,” Heim says. “This could allow the treatment to remain effective even when the vulnerabilities differ from tumor to tumor.” Some two- and three-drug combinations outperformed individual drugs, and certain three-drug combinations affected non-tumor liver organoids far less than cancer models, suggesting more selective targeting. 

The team then tested regorafenib, selinexor, and ixazomib together in mice with tumors derived from patient organoids; the triple therapy slowed tumor growth more effectively than regorafenib alone, without significant added toxicity in the model studied. Further studies are needed, since organoids only incompletely capture blood vessels, immune cells, and other parts of a tumor's microenvironment.